Generic Name and Formulations:
Varenicline (as tartrate) 0.5mg, 1mg; tabs.
Indications for CHANTIX:
Smoking cessation aid.
Provide patients with counseling and educational support. Set a target "quit date". Begin therapy 1 week before target quit date. Alternatively, may begin therapy and then quit smoking between Days 8 and 35 of treatment. Take after eating with a glass of water. ≥18yrs: initially 0.5mg once daily on Days 1–3, then 0.5mg twice daily on Days 4–7, then 1mg twice daily thereafter. May reduce dose if intolerable nausea or other adverse effects occur. Treat for 12 weeks; may continue 12 more weeks if patient successfully stops smoking to further increase the likelihood of abstinence. Patients who are not able or willing to quit abruptly: consider a gradual approach; begin Chantix dosing and reduce smoking by 50% from baseline within the 1st four weeks, by an additional 50% in the next four weeks, and continue reducing with the goal of complete abstinence by 12 weeks; continue for a total of 24 weeks of treatment. If patient motivated to quit and did not succeed, encourage another attempt with Chantix once factors contributing to failed attempt have been addressed. Severe renal impairment: initially 0.5mg once daily; may titrate to max 0.5mg twice daily. ESRD with hemodialysis: max 0.5mg once daily if tolerated.
<18yrs: not established.
Monitor for neuropsychiatric adverse events (eg, behavioral changes, agitation, depression, suicidal ideation); evaluate and consider dose reduction, continue therapy under closer monitoring, or discontinuation if occur. Pre-existing psychiatric disorders. History of seizures or other factors that can lower seizure threshold. Cardiovascular disease; monitor for new or worsening signs/symptoms. Renal impairment. Elderly. Pregnancy. Nursing mothers: monitor infant.
May affect alcohol tolerance; reduce alcohol consumption until effects are known. Smoking cessation may affect metabolism of other drugs (eg, warfarin, theophylline, insulin). Increased adverse effects with nicotine replacement therapy.
Nicotinic receptor partial agonist.
Nausea, other GI effects (eg, constipation, flatulence, vomiting), sleep disturbance (eg, abnormal dreams, insomnia); nicotine withdrawal symptoms (due to smoking cessation), neuropsychiatric symptoms (may be serious), cardiovascular events; seizures, somnambulism, angioedema, hypersensitivity reactions, serious skin reactions (rare); discontinue if occurs.
Tabs—56; Starting 2-week card (0.5mg x 11 tabs + 1mg x 14 tabs)—1; Continuing 2-week card (1mg x 28 tabs)—1; Starting 4-week card (0.5mg x 11 tabs + 1mg x 42 tabs)—1; Continuing 4-week card (1mg x 56 tabs)—1; Starting Month Box (0.5mg x 11 tabs + 1mg x 42 tabs)—1; Continuing Month Box (1mg x 56 tabs)—1
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Mortality Rates for Substance Use Disorders, Intentional Injuries Vary Widely By Country
- Facial Emotion Recognition Differentiates Behavioral Variant Frontotemporal Dementia From MDD
- The Challenge of Helping Uninsured Patients While Protecting Practice Finances
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Examining Associations Between Diabetes and Effects on Cognition